Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The report specifically addresses the notification of transactions involving directors and persons discharging managerial responsibility under the Deferred Investment Award Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
On April 11, 2011, the Administrators of the Deferred Investment Award Plan notified the Company of an increase in notional interests in Ordinary shares for specific individuals. This increase resulted from the re-investment of the dividend paid to shareholders on April 7, 2011, at a price of £12.19 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Re-investment of dividends into notional Ordinary shares under the Deferred Investment Award Plan.
- Transaction Date: April 11, 2011 (Notification date); April 7, 2011 (Dividend payment date).
- Share Price: £12.19 per share.
- Individuals Notified: Mr E J Gray, Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Dr P J T Vallance, and Mrs V A Whyte.
- Financial Data: No financial performance metrics are included in this specific filing.